The liver cancer therapeutics market was valued at $382.2m in 2009, indicating a growth rate of 27.1% between 2001 and 2009. Until the market entry of Nexavar (sorafenib) in 2007, the liver cancer therapeutics market was growing at a rate of only 9%. Up until now, Nexavar has been the only approved drug for the treatment of liver cancer. Even though Nexavar extends overall survival by only three months, the drug is widely prescribed in the US and in some countries in Europe. The late-stage clinical development pipeline consists of many first-in-class and me-too drugs that are effective and safe for liver cancer patients. Once these drugs enter the market, the market will grow further at a significant rate. GlobalData estimates that the liver cancer therapeutics market in 2017 will be $1.2bn.

High Unmet Needs Exist in the Liver Cancer Therapeutics Market in Terms of Efficacy and Safety

The liver cancer market has high unmet needs in terms of both efficacy and safety. More than 90% of patients diagnosed with liver cancer are between 45 years and 85 years of age. Nexavar is the only available Food and Drug Association (FDA) approved treatment for advanced liver cancer patients. However, the median survival time in patients treated with Nexavar is only three months more than for patients treated with a placebo. Moreover, Nexavar has a low safety profile. About 39% and 6% of Nexavar-treated patients reported grade 3 and grade 4 adverse reactions respectively.

The Liver Cancer Pipeline is Very Strong with Many New First-In-Class Drugs in Late-Stage Clinical Development

The liver cancer pipeline is very strong, with approximately 54 molecules in the various stages of development. The majority of these molecules are first-in-class molecules that act on new receptors with new mechanisms of action. The late-stage pipeline is inundated with many first-in-class molecules, such as Miripla (miripaltin), and S-1. Miripla was approved in Japan for the treatment of Hepatocellular Carcinoma (HCC) in January 2010. The drug is undergoing clinical trials in the US and Europe and is expected to receive regulatory approval by 2011. The first-in-class molecules are primarily Tumor Necrosis Factor alpha (TNF-alpha) inhibitors, selective estrogen receptor modulators and light activated therapies.

Scientists from San Antonio make a breakthrough when they discover a new drug which is said to be greatly effective in curing hepatitis C, a disease that damages the liver of the patient. The hepatitis C virus or HCV is spread by blood to blood contact. Most people infected by the disease do not show any sign or symptoms initially, yet once established, chronic infection can damage the liver. It is estimated that around 300 million people worldwide are infected by hepatitis C.

In a test conducted at the South West Foundation for Biomedical Research, 35 chimpanzees from north-west San Antonio was used to fight against the killing disease. As Chimpanzees are the only animals that can be infected by hepatitis C other than humans, they play a key role in this test.

Over the past few years, Robert Lanford, Ph.D. and his team members had been conducted a half a million study. It is called the locked nucleic acids which is a DNA based therapy that does not directly target the virus, but creates blockage for a molecule in liver that is required for the replication of the virus. In this way, the invader is essentially starved. Result from the study show an amazing 350 fold drop in the virus levels after the treatment. It is more surprising that the virus levels continued to decrease even after 3 months of stopping the therapy.

With the use of liver biopsies, a medical test involving the removal of cells or tissues for examination, scientist found that the livers of the chimpanzees were becoming healthier, even when the experimental therapy was taking place. Lanford added that the best part of the therapy is that no anti-viral resistance was created by the drug.

Santaris Pharma A/S, the company from Denmark which produces the drug, is starting to conduct the test on humans. The company claims that, it will take 3 more years before the drug will become available in the market.

In the mean time, the scientists are happy about what can be a new way for targeting other diseases as well. Lanford said that they already expected that the drug will be effective in lowering HCV levels, but they had no idea that the test will be successful to such a great extent. He said that they feel that it will be a very safe medicine that can be consumed for a long term. As per Lanford’s opinion, this is a key breakthrough.

All around the world, 170 million people are suffering from hepatitis C, which serves as one of the main reasons for liver transplantations. Around 4% of adults in America are infected by the disease and this report should give some new hope to them.

According to a recent study conducted by US researchers, smokers who light up a cigarette first thing in the morning display higher levels of nicotine than those who wait after their breakfast; this is regardless of how many cigarettes they smoke throughout the day. In the study, smoker’s levels of cotinine which reflects the risks of developing lung cancer have been measured. Continine is the metabolic byproduct of nicotine used to measures how much cigarette smoke entering a smoker’s body.

The study conducted by the Penn State College of Medicine suggests that earlier smokers will require more help to give up this habit. The study which include over 250 healthy people who smoke every day was published in the Cancer Epidemiology, Biomarkers and Prevention. The reasons why these levels were different are still unclear, but they probably reflect more intense smoking manners among those who smoke first thing in the morning. Their need for a cigarette is proved to be greater than the people who can wait.

Smokers who smoke 20 cigarettes in a day have different levels of cotinine, with top levels as much as 75 times higher than the lowest levels. The highest levels are visible among people who smoke within 30 minutes of waking up, the section of people who is categorized in high dependency levels. Joshua Muscat, the professor of public health at the Penn State College of Medicine, says that these people require more intense intervention than the other smokers so that they can quit smoking on a permanent or sustained basis.

Joshua Muscat, the author of the report, says that all smokers are not same. Trying to reduce smoking may require accounts for smoking behavior of the individuals such as frequency and intensity of puffing, physiological symptoms and cravings.

A spokesperson from the Roy Castle Lung Cancer Foundation has appreciated this research and said that it will prove to be helpful in further understanding the smoking habits of people and also their addiction to tobacco. He added that because this is a small study, which include only 252 participants, the results should be observed carefully. It is still not sure that whether other major conclusions regarding smoking cessation in future can be made out of this study, however he agrees with the author of the study that more research is still required in this area.